Brenntag SE Earnings Recaps
Q3 2025
Nov 14, 2025
Brenntag SE's Q3 2025 performance reflects resilience amid challenging market conditions, with a focus on enhancing sales and operational efficiency under new CEO Jens Birgersson’s leadership.
Key takeaways
- Implementing immediate sales focus to strengthen customer relationships and drive revenue, rather than waiting for market recovery.
- Decision-making processes are being streamlined by removing bureaucratic layers to enhance responsiveness and efficiency.
- Emphasis on executing cost reduction initiatives to align the cost structure with current market realities and boost competitiveness.
Q2 2025
Aug 13, 2025
Brenntag SE reported a challenging second quarter in 2025, with sales declining 4% year-over-year to EUR 3.9 billion, attributed to geopolitical tensions and demand slowdown. Operating EBITA saw a significant decrease of 14%, leading to adjusted guidance for the full year amidst ongoing pressures.
Key takeaways
- Operating gross profit fell by 2% to EUR 974 million, with gross profit as a percentage of sales at 25.2%.
- Free cash flow generated was EUR 153 million, supporting underlying cost management amid rising operational expenses.
- The company adjusted its full-year operating EBITA forecast to EUR 950 million to EUR 1.050 billion, reflecting ongoing economic uncertainties.
- Successful acquisitions, including MCE Pharma, position Brenntag to enhance its biopharma market presence and service offerings.
- Recognition for sustainability efforts was highlighted, with a Gold rating from EcoVadis and an A- rating in the latest CDP climate assessment, underscoring commitment to environmental goals.